Why the study?
Does cis-platinum improve response rates in patients with measurable metastases from primary carcinoma of the bladder?
Does cis-platinum improve response rates in patients with measurable metastases from primary carcinoma of the bladder?
Cis-platinum demonstrated a 26% response rate in patients with metastatic recurrent bladder carcinoma.
Cisplatin shows activity in metastatic bladder cancer; hypothesis-generating and should not change practice without randomized trials.
Summary— A series of 27 patients with measurable metastases from primary carcinoma of the bladder received cis‐platinum 50 mg/m 2 /3‐weekly. Twenty‐six per cent (32% if patients receiving only one injection are excluded) responded for a median of 4 months.
No takes yet. Share an insight, caveat, or question.
Williams et al. (1981) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: